Google DeepMind dismantles Nobel Prize-winning AlphaFold team in strategic shift to Gemini

Google DeepMind Reshuffles Nobel Prize-Winning AlphaFold Team

Google DeepMind has dismantled the team behind AlphaFold, its groundbreaking AI system that earned a Nobel Prize in Chemistry in 2024. The majority of original authors from the AlphaFold papers have been reassigned over the past year, according to an analysis by the Financial Times1

1

. This strategic shift marks a fundamental change in how one of the world's leading AI laboratories approaches scientific research.

DeepMind confirmed that staff members have moved internally to projects centered around Google's Gemini large language models, as well as specialized areas including enzyme design, nuclear fusion, and genomics1

1

. Others have relocated to Isomorphic Labs, Alphabet's drug discovery company that was spun out from DeepMind in 2021 to commercialize AlphaFold's breakthroughs2

2

. Nearly a quarter of the full-time Google DeepMind authors of the original AlphaFold papers have left the company altogether1

1

.

Strategic Shift From Grand Challenges to AI Scientist Systems

The reshuffle reflects how DeepMind's scientific strategy has evolved since the rise of large language models. "Our strategy over the last nine years has been to focus on grand challenges... a concrete goal every project is focused on," said Pushmeet Kohli, vice-president of research at Google DeepMind, where he founded and leads the AI for Science team. "The strategy has evolved"1

1

.

Rather than organizing researchers around single scientific problems like the protein folding problem, the AI lab now focuses on building Gemini-powered systems designed to assist scientists and eventually automate parts of the scientific process4

4

. This puts DeepMind in direct competition with OpenAI and Anthropic to develop frontier AI agents capable of accelerating AI-driven scientific research1

1

.

Key Scientists Join Anthropic in Surprising Exodus

The most significant departures involve core members of the AlphaFold team moving to competitor Anthropic. John Jumper, who shared the 2024 Nobel Prize with DeepMind CEO Demis Hassabis for their work on protein structure prediction, announced in June that he was leaving for Anthropic2

2

. He will be joined by Jonas Adler and Alexander Pritzel, both instrumental AlphaFold researchers1

1

.

Earlier this year, Jumper and Adler had moved to Google's internal "Code Strike" team, assembled to improve the company's AI coding capabilities1

1

. A DeepMind employee told the FT that all three had been "instrumental, important, core members" and that their departures "sparked surprise internally"3

3

. They now join a rival that recently launched Claude Science, a workbench built specifically for biology and drug discovery work3

3

.

AlphaFold's Legacy and the Broader Industry Shift

AlphaFold, which DeepMind began developing in 2018, transformed biological research by using AI to predict three-dimensional protein structures in minutes instead of years2

2

. The system solved humanity's 50-year-old protein folding problem, which sought to answer how amino acids automatically fold into complex 3D shapes that determine a protein's biological role2

2

.

In 2021, Nature published papers detailing AlphaFold's methodology and structure predictions of the entire human proteome. DeepMind then launched the AlphaFold Protein Structure Database, providing researchers free access to over 200 million protein structure predictions2

2

. Scientists had identified structures of roughly 170,000 proteins over 50 years using traditional tools; AlphaFold accelerated this dramatically and is now used to speed drug discovery, develop vaccines, and understand structural changes in proteins associated with neurodegenerative diseases like Alzheimer's and Parkinson's2

2

.

The reorganization reflects a broader shift across frontier AI labs, which increasingly view large language models not simply as chatbots but as tools capable of accelerating scientific research1

1

. Competition for the small pool of researchers capable of building frontier AI systems has intensified alongside this shift. "[AI researchers] want to work for a lab that is at the frontier and [not] have to play a catch-up game," Mark Chen, OpenAI's head of research, told the FT1

1

.

DeepMind maintains it remains "incredibly proud" of its scientific heritage and AlphaFold's global impact, which inspired the launch of Isomorphic Labs1

1

. The company has since struck partnerships with pharmaceutical companies including Novartis and Eli Lilly as it seeks to use AI to accelerate drug discovery1

1

. Whether this focus on Gemini and AI agent development will yield breakthroughs comparable to AlphaFold remains to be seen.